Study of Proton Radiation to the Brain and Spinal Cord for Patients With Leptomeningeal Metastases

Phase 1

Completed

• Conditions: Leptomeningeal Metastases

• Registration Number: NCT03520504
• Lead Sponsor: Memorial Sloan Kettering Cancer Center

Brief Summary

The purpose of this study is to find the safest and most effective dose for delivering proton beam to the space containing CSF, brain, and spinal cord, in treating leptomeningeal metastases. The researchers think that using proton beam radiation to treat the space containing CSF, brain, and spinal cord, instead of treating only the areas where the metastasized tumor cells are causing symptoms, would improve the treatment of this disease.

Detailed Description

Not available

Study Timeline

• Study Start: 2018-04-26
• Study First Submitted: 2018-04-27
• Study First Submitted QC: 2018-04-27
• Study First Posted: 2018-05-09
• Status Verified: 2022-12
• Primary Completion: 2022-12-22
• Study Completion: 2022-12-22
• Last Update Submitted: 2022-12-22
• Last Update Posted: 2022-12-23

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 24

Inclusion Criteria

• Female subjects must either be of non-reproductive potential (i.e. post-menopausal by history: >/= 60 years old and no menses for 1> year without an alternative medical cause; OR history of hysterectomy, OR history of bilateral tubal ligation, OR history of bilateral oophorectomy) or must have a negative serum pregnancy test within 2 weeks prior to starting treatment.

• Patient with solid tumor malignancy with leptomeningeal metastases established radiographically and/or through CSF cytology.

• KPS ≥ 60.

• Age ≥ 10 years.

• For adult patient, the patient is able to provide informed consent. For pediatric patient, a parent is able to provide informed consent.

• Patient at reproductive potential must agree to practice an effective contraceptive method.

• Adequate bone marrow function:

  • Hemoglobin ≥ 8g/dL
  • Absolute neutrophil count ≥500/mm^3
  • Platelet count ≥ 100,000/mm^3

Exclusion Criteria

• Patient with multiple, serious major neurologic deficits including encephalopathy.
• Patient with extensive systemic disease and without reasonable systemic treatment options.
• Patient who is unable to undergo MRI brain and spine with gadolinium contrast.
• Previous radiotherapy to the intended treatment site that precludes developing a treatment plan that respects normal tissue tolerances.
• Pregnant or lactating women.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Primary Outcome Measures

Name	Time	Method
number of patients with dose-limiting toxicity	2 years	will be assessed by physician-graded CTCEAv4

Trial Locations

Locations (8)

Memorial Sloan Kettering Basking Ridge; 🇺🇸 Basking Ridge, New Jersey, United States

Memorial Sloan Kettering Monmouth; 🇺🇸 Middletown, New Jersey, United States

Memorial Sloan Kettering Bergen; 🇺🇸 Montvale, New Jersey, United States

Memorial Sloan Kettering Commack; 🇺🇸 Commack, New York, United States

Memorial Sloan Kettering Westchester; 🇺🇸 Harrison, New York, United States

Memorial Sloan Kettering Cancer Center; 🇺🇸 New York, New York, United States

Memorial Sloan Kettering Rockville Centre; 🇺🇸 Rockville Centre, New York, United States

Memorial Sloan Kettering Nassau; 🇺🇸 Uniondale, New York, United States